Sicart Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$35.2M |
| 2 |
Airbnb
ABNB
|
+$5.31M |
| 3 |
Adobe
ADBE
|
+$5.09M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$3.95M |
| 5 |
Guardant Health
GH
|
+$3.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MP Materials
MP
|
+$13.1M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$1.02M |
| 3 |
Emerson Electric
EMR
|
+$300K |
| 4 |
Rockwell Automation
ROK
|
+$257K |
| 5 |
Campbell Soup
CPB
|
+$226K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 14.44% |
| 2 | Healthcare | 12.27% |
| 3 | Consumer Discretionary | 10.84% |
| 4 | Materials | 8.47% |
| 5 | Consumer Staples | 8.3% |
Similar funds
Sicart Associates's Q3 2025 Portfolio in Review
As of Q3 2025, Sicart Associates held 75 positions worth $369M, up 29% from $286M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Sicart Associates deployed $45.9M of net new capital in Q3 2025, opening 3 new positions and adding to 21 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 6,981 shares worth $3.93M.
By sector, the portfolio is most concentrated in Communication Services at 14% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was MP Materials, an estimated $13.1M trimmed.
- Sicart Associates's largest Q3 2025 buy was Regeneron Pharmaceuticals: 6,981 shares worth $3.93M.
- Sicart Associates added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q3 2025, an estimated $35.2M increase.
- Sicart Associates's biggest Q3 2025 reduction was MP Materials, cutting an estimated $13.1M.
- Sicart Associates fully exited Emerson Electric in Q3 2025, selling an estimated $300K.
- Sicart Associates's ten largest holdings make up 51% of its $369M portfolio in Q3 2025.
- Sicart Associates opened 3 new positions and closed 2 in Q3 2025.
- Sicart Associates's portfolio value rose 29% quarter-over-quarter to $369M.
Based on Sicart Associates's 13F filing for Q3 2025, filed 7 Oct 2025.